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Introduction {#sec1}
============

Prostate cancer is the most common cancer in men and the second leading cause of cancer-related mortality in the Western world ([@bib13]). Androgen deprivation therapy (ADT) is widely used to treat prostate cancer, but one-third of the patients will develop resistance to ADT, which is called castration-resistant prostate cancer (CRPC) ([@bib19]). In general, patients with prostate cancer progress into CRPC in 18--48 months, and most deaths result from metastatic CRPC (mCRPC) with a median survival time of fewer than 2 years ([@bib7]). There are many other therapeutic options available for patients with progressive cancer. Docetaxel is one of the first-line treatments for mCRPC ([@bib15]). It has been shown that combined with prednisone, 75 mg/m^2^ docetaxel treatment for 3 weeks significantly reduced pain and improved overall survival time and quality of life in phase III trials ([@bib40]).

Although many studies have proved the positive effect of docetaxel on population-level survival ([@bib3], [@bib27]), some patients become resistant to the therapy and stop the treatment ([@bib31]). Approximately 10%--20% of the patients who were initially under docetaxel treatment discontinued the therapy owing to toxicity-induced adverse events (AEs) ([@bib43]). Since docetaxel-based chemotherapy is still an essential treatment for mCRPC and hormone-sensitive metastatic prostate cancer ([@bib39]), it is important to identify whether a patient is able to tolerate the docetaxel therapy. However, whether the early discontinuation is predictable based on the clinical characteristics of a patient remains unclear ([@bib35]).

Recognizing the critical clinical need for identifying patients who are expected to suffer from immediate adverse events upon docetaxel treatment, the international Dialogue for Reverse Engineering Assessment and Methodology (DREAM) committee organized the Prostate Cancer Challenge, which called for the research community to develop algorithms for predicting AE ([@bib35]). In this challenge, a benchmark dataset was held out to systematically evaluate different computational methods. Here we report a model based on our winning solution to this challenge, which ranked first among 34 participating teams. In this model, we use 78 features associated with the laboratory test, metastases data, patient clinical features, and medical history. We find that the survival status is highly informative, complementing the prediction of discontinuation. We further reveal important predictive features that can be directly used to guide treatment in clinical settings. The model presented in this study not only sets the state of the field for personalized modeling of mCRPC treatment but also provides potential biomarkers and risk factors in the future prostate cancer treatment.

Results {#sec2}
=======

Overview of the Experimental Design for Predicting Treatment Discontinuation in Prostate Cancer {#sec2.1}
-----------------------------------------------------------------------------------------------

The schematic illustration of our experimental design is shown in [Figure 1](#fig1){ref-type="fig"}. In this study, we used the data collected at three different cohorts from a total of 1,600 patients in phase III prostate cancer clinical trials [Table 1](#tbl1){ref-type="table"}. To address the cohort and batch effects, the original data were processed through missing value imputation and normalization (see details in [Methods](#sec4){ref-type="sec"}). We tested and compared different types of machine learning models via the standard 5-fold cross-validation experiments. The prediction performance was evaluated by area under the receiver operating characteristic curve (AUC) ([@bib4]) and area under the precision-recall curve (AUPRC). To understand the crucial features in predicting treatment discontinuation, we further performed feature importance analysis and identified top contributing features.Figure 1The Workflow of the Algorithm Design for Predicting Early Discontinuation of Treatment in Prostate CancerThe overall workflow consists of three main parts: (1) Data Collection; (2) Data Processing; (3) Model Construction & Inspection. Data were collected from three cohorts. In data processing, 78 features were used and normalized. Missing values were imputed. We generated two sets of gold standards for the subsequent model fitting, in which "New" (right in the "Data Processing" part) represents the gold standard assembled by the death, discontinuation, and treatment statuses. The "Model Construction & Inspection" part has three steps: (step 1) choose the best base learner; (step 2) construct a combinatory gold standard; (step 3) calculate the feature importance. All the performances were evaluated by randomly partitioning the data 10 times into 5-fold cross-validation, either on the full dataset or on an individual cohort. The final model submitted during the challenge was trained on the full dataset, which combined three cohorts.Table 1Patient Characteristics of the Three CohortsCohortsASCENT2 (ASC)CELGENE (CEL)EFC6546 (VEN)**Basic Information** \# Sample476526598 Median age (years)[a](#tblfn1){ref-type="table-fn"}716868**Discontinuation Status** % Discontinuation22.057.798.52 Median time to discontinuation (days)153.0211.0202.5 % Discontinuation records missing0.0018.060.00**Death Status** % Death28.9917.4972.41 Median time to death (days)357.0279.0642.5**Treatment Status** % AE9.0313.3121.07 % Possible AE46.8545.2422.24 % Progression19.9621.2955.68 % Complete24.160.000.17 % Treatment status records missing0.0020.150.84[^3]

We first tested the prediction performance of five base learners: (1) linear regression, (2) logistic regression, (3) Cox regression (using AE as an endpoint), (4) bootstrap aggregation classification and regression trees (BAG-CART) ([@bib38]), and (5) random forest (RF) ([@bib6]). The first three methods are linear or generalized linear statistical models, and the last two methods are nonlinear tree-based models. For this task of predicting treatment discontinuation primarily based on laboratory test and patient clinical features, we anticipated that the nonlinear interactions between input features would be crucial. We, therefore, investigated two tree-based methods, which have slightly different implementations---when building trees, BAG-CART considers all features for each node for a split and RF considers a random subset of features for each node for a split. We performed 5-fold cross-validation for ten times in two scenarios: (1) using the combined dataset of three cohorts (hereafter referred to as "the full dataset"; [Figures 2](#fig2){ref-type="fig"}A and 2B) and (2) using each cohort individually ([Figures 2](#fig2){ref-type="fig"}C and 2D).Figure 2Evaluation of Different Base Learning Using AUC and AUPRCThe (A) AUCs and (B) AUPRCs of five base learners trained on the full dataset are shown in different colors. The (C) AUCs and (D) AUPRCs of these base learners trained on each cohort individually were also calculated. The colored boxes or violins represent the values of 10 times 5-fold cross-validation of five models, and the white ones represent the baselines. Of note, the AUC baseline of random prediction is always 0.5 in different cohorts. In contrast, the AUPRC baseline will change, which equals the percentage of early discontinuation events in a particular cohort.

In general, the discontinuation status can be predicted by the models trained from clinical features with those widely used base learners. When trained and evaluated on the full dataset, all the five base learners achieved acceptable performances, and the tree-based methods, including BAG-CART and RF, performed relatively better than the other three ([Figures 2](#fig2){ref-type="fig"}A and 2B). Similarly, when trained and evaluated on each cohort individually, the tree-based methods consistently achieved good performance, whereas the linear, logistic regression and Cox regression model performed even worse than the random prediction baseline in EFC6546(VEN) ([Figure 2](#fig2){ref-type="fig"}C; [Table S1](#mmc1){ref-type="supplementary-material"}). The highest AUC scores were achieved by RF, RF, BAG-CART, RF, respectively in the full dataset and each of the three cohorts, where the median AUCs were 0.6269, 0.5701, 0.6562, and 0.5378 ([Figure 2](#fig2){ref-type="fig"}C). They also outperformed other base learners in terms of AUPRC, where the medians were 0.1999, 0.3080, 0.1792, and 0.0959 ([Figure 2](#fig2){ref-type="fig"}D). Of note, the average baseline AUPRCs of random prediction were 0.1308, 0.2146, 0.0952, and 0.0885, reflecting the overall ratio of positive cases. Since BAG-CART and RF are similar tree-based models and RF achieved the highest performance in two of the three cohorts and the full dataset, we chose RF as our base learner in the following analysis.

Cross-Reference Multiple Labels Improves Prediction Performance {#sec2.2}
---------------------------------------------------------------

To improve the performance of our model, we carefully inspected the dataset and found that multiple labels provided non-redundant information. The original definition of discontinuation was whether an AE occurred within 92 days. According to this definition, patients with AE at 93 days (high risk to discontinue) or 393 days (low risk to discontinue) were indistinguishable and their labels were identical. A major challenge was how to integrate this hidden information into a model. In fact, the death and treatment statuses were highly associated with the discontinuation. And a patient who died early (within 3 months) could be, although not definitely, associated with an adverse event. Therefore, we treated early death as another type of "adverse event" and assumed that patients labeled by "AE" and "possible AE" in treatment status should have a higher risk to discontinue than those labeled by "progress" and "complete." These labels are intermediate variables reflecting diverse categories of the discontinuation reason, where "progress" means the treatment is in progress without AE and "complete" means the treatment has finished without AE.

Therefore, we integrated death status, discontinuation status. and treatment status (AE, possible AE, progression and complete) and created a new gold standard, retaining the original labels for a fair comparison. Specifically, we re-labeled the original discontinuation status: if a patient had AE or possible AE, or died early during the study, we treated this patient as a "discontinuation" case (see [Methods](#sec4){ref-type="sec"}). The distributions of the original and new labels are shown in [Figures 3](#fig3){ref-type="fig"}A and 3B, respectively. Notably, the high-risk patients (red) to discontinue treatment are separated from the low-risk ones (yellow and orange). Then we re-trained our model using this new gold standard and compared it with the model trained on the original discontinuation label. In all three cohorts, the performance was improved using the new gold standard ([Table S2](#mmc1){ref-type="supplementary-material"}, [Figures 3](#fig3){ref-type="fig"}C and 3D). The AUC scores were increased to 0.6356, 0.5726, 0.6420, and 0.547, and the AUPRC scores were increased to 0.2001, 0.3089, 0.1598, and 0.1006, in the full dataset, ASCENT(ASC), CELGENE(CEL), and EFC6546(VEN) cohorts, respectively. This result indicates that the discontinuation label alone cannot fully reflect the status of a patient; the death and treatment status provides important and complementary information for more accurate predictions.Figure 3Comparison of Models Using the Original Discontinuation Labels and New LabelsWe evaluated the performance of our model using two types of gold standards: (A) the original discontinuation status and (B) our new gold standard integrating both treatment and death status. The colors represent the treatment status of each sample, and the shapes represent the death status. The vertical dash line is placed at 93 treatment days, which is the original time threshold of early discontinuation. The early death cases are re-labeled as positive, which are more likely caused by the treatment adverse events. Models using labels defined by different gold standards are evaluated by (C) AUC and (D) AUPRC. "Discontinuation" represents the model using labels of the discontinuation status, and the "New standard" represents the model using labels of the new gold standard. Notably, the AUC baseline is a constant 0.5 (so that it is a horizontal line instead of a box), whereas the AUPRC baseline changes along with the partition of the dataset.

Inspection of Important Features in Predicting Treatment Discontinuation {#sec2.3}
------------------------------------------------------------------------

To find the key determinants of treatment discontinuation, we investigated the feature importance by calculating the delta-error of each feature in our random forest model (see [Methods](#sec4){ref-type="sec"}), on both the full dataset and subsets (ASC + CEL; CEL + VEN; VEN + ASC). We also colored the features according to their categories defined in the previous study ([@bib35]).

The top contributing features of models trained the full dataset and three individual cohorts are shown in [Figure 4](#fig4){ref-type="fig"}A and [Figure S1](#mmc1){ref-type="supplementary-material"}, respectively. In general, laboratory test features play more important roles in this model, and the top 10 important features are consistent among different datasets ([Figures 4](#fig4){ref-type="fig"}B--4D, starred features). However, we also notice that, when trained on the combined dataset of CEL and VEN, the situation is different ([Figure 4](#fig4){ref-type="fig"}C). This may result from the cohort effects, which we will discuss in detail later. To investigate the impact of these features on patients with mCRPC, we first tested the linear relationship (Pearson\'s correlations) between the top 10 features and the risk of discontinuation on patients with mCRPC ([Table S3](#mmc1){ref-type="supplementary-material"}). We observed that the impact of an individual feature on the discontinuation risk was weak because these clinical features had complex nonlinear interactions, which cannot be reflected by linear Pearson\'s correlation. This is also why the random forest model outperformed other base learners for this prediction task since the random forest was able to learn the non-linear interactions between features and robust to outliers or noises when the dataset is relatively small. We further calculated the correlations between the prediction of the random forest model using only the top 10 features and the treatment discontinuation (the last row in [Table S3](#mmc1){ref-type="supplementary-material"}). This prediction can be regarded as a new non-linearly "combined" feature based on the top 10 features, and it has a much higher and significant correlation with the discontinuation risk on mCRPC patients.Figure 4The Feature Importance Map of All 78 Features used in Our Model(A) The importance of all features (features with negative importance have been removed). The top 10 important features are ALB, NA., TPRO, MG, TESTO, WBC, PHOS, MHVASC, NEU, and MHSOCIAL, which represent albumin, sodium, total protein, magnesium, testosterone, white blood cell, phosphorus, medical history of vascular disorders, neutrophils, and medical history of social circumstances, respectively. The colors of the bars represent the categories that the features belong to, and the sub-boxplot summaries the feature importance in each category. Note that there is only one feature that belongs to metastases.(B--D) Top 10 important features in different subsets of data (B: ASC + CEL, C: CEL + VEN, D: VEN + ASC) are also presented here, where the stars represent the overlaps between them and the overall top 10 in panel A.

The top 10 important features are ALB (Albumin), NA. (Sodium), TPRO (Total Protein), MG (Magnesium), TESTO (Testosterone), WBC (White Blood Cells), PHOS (Phosphorus), MHVASC (Medical History: Vascular Disorders), NEU (Neutrophils), and MHSOCIAL (Medical History: Social Circumstance). Most of them play important roles in cancer-related diagnosis, prognosis, and therapy in previous studies, especially the biological features including serum albumin, sodium, magnesium, testosterone, phosphorus, and neutrophils ([@bib14]). Our findings are not incidental; in fact, many previous studies have reported these features for predicting the survival of patients with mCRPC. Serum albumin can be used to predict prognosis and recurrence for patients with prostate cancer ([@bib34], [@bib46]); neutrophils is also regarded as a prognostic factor ([@bib21], [@bib36], [@bib42]), especially for the patients with mCRPC with docetaxel chemotherapy ([@bib49]). Sodium (Na) and magnesium (Mg) regulate and influence cancer development as ions and compounds: sodium compounds can affect prostate cancer cell activities and the function of related proteins ([@bib2], [@bib16]), whereas the rate of Ca^2+^/Mg^2+^ is significantly associated with the risk and proliferation ([@bib8], [@bib37]). Phosphorus, as another important chemical element for humans, has also been proven to be associated with the risk of high-grade prostate cancer ([@bib48]). And testosterone is also used as a therapeutic strategy and a predictive feature ([@bib1], [@bib28], [@bib29]), although its relationship with prostate cancer is controversial ([@bib17]). Of note, these top features are highly associated with predicting treatment discontinuation, yet they do not imply causation. In this study, we focused on developing accurate machine learning models based on large datasets from three independent cohorts and identified the cross-cohort putative risk factors associated with (instead of causing) treatment discontinuation. Identifying etiological features requires further data collection and experimental validation, which is beyond the scope of this paper. Nevertheless, we here summarize literature evidence about these potential causal factors, which could provide guidance for future experimental design.

Validation on an External Cohort by Blind Test via the DREAM Platform {#sec2.4}
---------------------------------------------------------------------

The validation of prediction was carried out through an objective evaluation venue. The international DREAM consortium had created a framework to unbiasedly evaluate the accuracy of different models ([@bib12]). The participants were provided with the training data and the gold standard, and the test data, whereas the validation gold standard was hidden from participants. Then, through an online platform, the participants submitted a one-shot prediction file, which was evaluated automatically on the server.

Different gold standard creations and machine learning methods were explored by 34 teams during the challenge ([Figure 5](#fig5){ref-type="fig"}A). The basic gold standard labels are the discontinuation status (DISCONT) and censoring date (ENTRT_PC) of a patient, which were prevalently used by most teams (blue tiles in [Figure 5](#fig5){ref-type="fig"}A left). However, the death status (DEATH), date (LKADT_P), and the adverse effect (ENDTRS_C) of a patient were only used in our method, except for the death status was used once by another team. We integrated all these features and reconstructed the gold standard, which achieved the highest AUPRC for predicting discontinuation (the red model in [Figure 5](#fig5){ref-type="fig"}A). This comparison together with our cross-validation result suggests that gold standard reconstruction by capturing multiple sources of information was an important component of our high performance. Moreover, the base learners used by the participants were summarized and RF was used most by 14 of 34 teams. This suggests that the curation of the gold standard, rather than the exact machine learning base learner, distinguished our method from others.Figure 5A Summary of the Challenge ResultsAll data were the final round results and retrieved from the challenge official website. Considering the potential privacy problems, all the team names except ours are hidden in this figure.(A) Information of gold standard constructions, model categories, and learning strategies of the 34 teams (the left heatmap), as well as the final AUPRC estimation results (the right barplot). In summary, there were five variables used in the gold standard construction and 13 types of base learners. The participants mainly used ensemble study (Ensembl in heatmap x axis) to improve their models, and some of them reconstructed the gold standard (Reconstruction in heatmap x axis) for better performance. The blue tiles in the heatmap represent the variables or base learners used by the teams, whereas the white ones represent variables/learners that were not used. The gray tiles represent the missing information, and the red ones highlight our method. The barplot on the right shows the final AUPRC scores, where the dashed line represents the baseline of the validation data: 0.104.(B) The p value of how significant a model is better than the score of 5,000 random predictions.(C) The Bayes factor for the top performers. The Bayes factor is calculated by comparing each team with the best performer.

The validation cohort of this challenge comes from the comparative arm (docetaxel-placebo) of ENTHUSE33 ([@bib9]), a phase III trial previously designed for studying the effect of Docetaxel in Combination With Zibotentan in Patients With mCRPC, including 470 patients. Although the failure of the trial results was previously published, the data were not publicly available, allowing it to be used as an independent validation cohort in this study. In this validation cohort, our algorithm achieved the top performance among the competing teams with an AUPRC of 0.190, compared with the random baseline of 0.104 (p = 0.003, [Figure 5](#fig5){ref-type="fig"}). It means that if today\'s therapy would have mistakenly put an expected 104 out of 1,000 patients to docetaxel treatment, with our algorithm deployed in place, we will be able to move (0.190--0.104)/(1--0.104)∗104, approximately 10 patients out of a wrong therapy. As with any personalized medicine algorithm using machine learning, a perfect prediction is our DREAM to pursue, but it is still a dream. However, translating this 10 of 104 patients into a type of cancer that affects the largest number of men in this world, it is expected to have a significant impact on the care to our patients.

Discussion {#sec3}
==========

In this work, we report a machine learning model for predicting the docetaxel treatment discontinuation in mCRPCs. We find that tree-based methods are suited to this problem and outperform the Cox regression, one of the most popular methods in survival analysis. This phenomenon originated from the nature of the clinical dataset, where the features had complicated high-level interactions with each other in determining the treatment discontinuation. Tree-based methods are good at constructing models on a complex or non-linear dataset, and random forest applies the strategy of training on different parts of the dataset and averaging multiple decision trees to reduce the variance and avoid overfitting ([@bib5], [@bib23]); thus, tree-based methods, especially random forest, are more suitable for such problems.

Apart from the best base learner selection, we also observed that the assembled gold standard would generate better predictions than using discontinuation status alone. This result reveals that the mCRPC clinical features have potential relationships with the risk of discontinuation of patients, which was reflected by the treatment status and the discontinuation time in this dataset. A better method to evaluate the risk should give even better performance than ours because the binary combination cannot reflect the risk order entirely. Our work provides an attempt to integrate multiple information to address this problem. A dataset with continuous confidence labels instead of binary labels would facilitate method development in the future.

One limitation of this work results from the data availability. Most of the features in this dataset have more than 25% of their records missed ([Figure S2](#mmc1){ref-type="supplementary-material"}). This situation can be even more severe when considering the cohort individually, such as albumin (ALB), which is totally missing in ASC. To impute the missing values, we just simply replaced them with the average of the corresponding feature, which may introduce biases, and intensify the batch effects among cohorts and complexity among features. This should be another reason why linear, logistic regression and Cox regression failed to generate acceptable models. A more intact dataset should generate more precision models.

The clinical data itself is largely biased by cohort effects. The inconsistent results show not only in the feature importance calculation but also in our previous attempts to evaluate models cross cohorts even after normalizing. So we used t-distributed stochastic neighbor embedding (t-SNE) ([@bib45]) to visualize the differences among cohorts ([Figure S3](#mmc1){ref-type="supplementary-material"}). This figure shows the separation of these three cohorts, in which CEL and VEN have a closer relationship than to ASC. This explains why the results are inconsistent between the datasets with and without ASC.

Overall, our research provides a positive answer to the question of whether the early discontinuation can be predicted from basic clinical information and points out that random forest is the most suitable base learner. Our assembled gold standard performance also suggests that considering the risk of discontinuation for each patient rather than the binary label of early discontinuation can further improve the accuracy of prediction.

Limitation of the Study {#sec3.1}
-----------------------

1.Feature availability. Most of the features have more than 25% missing values. And some of them are even completely missing in one cohort, like albumin (ALB) in the ASC cohort. Our imputation using the average of non-missing values may introduce biases into their original distributions.2.Cohort effects. Data in the competition were provided by three providers, which could include cohort effects. Although we have normalized the whole data, our results indicate the existence of these effects. The performances vary when we built and tested models with and without the ASC cohort.3.Base model. In recent years, releases of Xgboost ([@bib51]) and LightGBM ([@bib50]) provide us more efficient and powerful tools for constructing and training tree-based models. They may achieve better performances than the random forest model.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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